Recent News

• 04.23.2025 - Mersana Therapeutics Announces Upcoming Emi-Le Oral and Poster Presentations at ASCO 2025 Annual Meeting
• 04.23.2025 - Mersana Therapeutics Announces Upcoming Emi-Le Oral and Poster Presentations at ASCO 2025 Annual Meeting
• 04.23.2025 - Mersana Therapeutics Announces Upcoming Emi-Le Oral and Poster Presentations at ASCO 2025 Annual Meeting
• 04.04.2025 - Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
• 04.04.2025 - Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
• 04.04.2025 - Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
• 04.01.2025 - Mersana Therapeutics Announces Upcoming Oral Presentation of Emi-Le Clinical Data at European Society for Medical Oncology (ESMO) Breast Cancer 2025 Annual Congress
• 04.01.2025 - Mersana Therapeutics Announces Upcoming Oral Presentation of Emi-Le Clinical Data at European Society for Medical Oncology (ESMO) Breast Cancer 2025 Annual Congress
• 04.01.2025 - Mersana Therapeutics Announces Upcoming Oral Presentation of Emi-Le Clinical Data at European Society for Medical Oncology (ESMO) Breast Cancer 2025 Annual Congress
• 03.11.2025 - Leerink Global Healthcare Conference

Recent Filings

• 04.18.2025 - PRE 14A Other preliminary proxy statements
• 04.17.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors